Population impact of stricter adherence to recommendations for pharmacological and lifestyle interventions over one year in patients with coronary heart disease

Journal of Epidemiology and Community Health

Volumn 59, Issue 12, 2005, Pages 1041-1046

  Gemmell, I ^a   Heller, R F ^a   McElduff, P ^a   Payne, K ^a   Butler, G ^a   Edwards, R ^a   Roland, M ^a   Durrington, P ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SPIRONOLACTONE;

CARDIOVASCULAR DISEASE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; DATA ANALYSIS; DEATH; HEALTH CARE; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; MAJOR CLINICAL STUDY; MORTALITY; NATIONAL HEALTH SERVICE; PATIENT; POPULATION RESEARCH; PRACTICE GUIDELINE; PREVALENCE; PRIMARY MEDICAL CARE; RISK REDUCTION;

AGED; EVIDENCE-BASED MEDICINE; FEMALE; GREAT BRITAIN; GUIDELINE ADHERENCE; HEART FAILURE, CONGESTIVE; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PRACTICE GUIDELINES; PREVALENCE; PRIMARY HEALTH CARE; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR;

EID: 28444434508     PISSN: 0143005X     EISSN: None     Source Type: Journal    
DOI: 10.1136/jech.2005.035717     Document Type: Article

References (61)

1. Heller RF, Dobson AJ. Disease impact number and population impact number: population perspectives to measures of risk and benefit. BMJ 2000;321:950-2.
2. Heller RF, Edwards R, McElduff P. Implementing guidelines in primary care: can population impact measures help? BMC Public Health 2003;3:7.
3. Heller RF, Page J. A population perspective to evidence based medicine: "evidence for population health". J Epidemiol Community Health 2002;56:45-7.
4. Department of Health. National service framework for coronary heart disease: modem standards and service models. London: Sationery Office, 2000.
5. Heartstats. http://www.heartstats.org/homepage.asp (accessed NOV 2004).
6. Cowie MR, Wood DA, Coats AJS, et al. Incidence and aetiology of heart failure-a population-based study. Eur Heart J 1999;20:421-8.
7. Capewell S, Livingston BM, MacIntyre K, et al. Trends in case-fatality in 117 718 patients admitted with acute myocardial infarction in Scotland. Eur Heart J 2000;21:1833-40.
8. Mant J, Hicks N. Detecting differences in quality of care-the sensitivity of measures of process and outcome in treating acute myocardial infarction. BMJ 1995;311:793-6.
9. Lyratzopoulos G, Cook GA, McElduff P, et al. Assessing the impact of heart failure specialist services on patient populations. BMC Health Services Research 2004;24:10.
10. Latini R, Tognoni G, Maggioni AP, et al. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin-systematic overview of individual data from 96,712 randomized patients. J Am Coll Cardiol 2000;35:1801-7.
11. National Primary Care Research and Development Centre, http://www.npcrdc.man.ac.uk/ResearchDetail.cfm?ID = 118&txtSearch = quip (accessed Jan 2005).
12. Royal Pharmaceutical Society of Great Britain. British National Formulary. London: British Medical Association, 2002.
13. Marshall T, Rouse A. Resource implications and health benefits of primary prevention strategies for cardiovascular disease in people aged 30 to 74: mathematical modelling study. BMJ 2002;325:197-9.
14. Almela P, Benages A, Peiro S, et al. Outpatient management of upper digestive hemorrhage not associated with portal hypertension: a large prospective cohort. Am J Gastroenterol 2001;96:2341-8.
15. Netten A, Curtis L. Unit costs of health and social care 2003. Canterbury: University of Kent at Canterbury, Personal Social Services Research Unit, 2003.
16. Cupples ME, McKnight A. Randomized controlled trial of health promotion in general practice for patients at high cardiovascular risk. BMJ 1994;309:993-6.
17. Greenland S. Interval estimation by simulation as an alternative to and extension of confidence intervals. Int J Epidemiol 2004;33:1389-97.
18. Primatesta P. Prevalence of cardiovascular disease. In: Health survey for England 1998. London: The Stationery Office, 1999.
19. Davies MK, Hobbs FDR, Davis RC, et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the echocardiographic heart of England screening study: a population based study. Lancet 2001;358:439-44.
20. MacIntyre K, Capewell S, Stewart S, et al. Evidence of improving prognosis in heart failure-trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation 2000;102:1126-31.
21. Baigent C, Sudlow C, Collins R, et al. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
22. Freemanrte N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730-7.
23. Ward S, Lloyd Jones M, Pandor A, et al. Statins for the prevention of coronary events. London: NICE, 2005.
24. Domanski MJ, Exner DV, Borkowf CB, et al. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction-a meta-analysis of randomized clinical trials. J Am Coll Cardiol 1999;33:598-604.
25. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease-a systematic review. JAMA 2003;290:86-97.
26. Bucher HC, Hengstler P, Schindler C, et al. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 2002;112:298-304.
27. Jolliffe J, Rees K, Taylor R, et al. Exercise-based rehabilitation for coronary heart disease. Cochrane Library. Chichester: Wiley, 2004.
28. Shibata MC, Flather MD, Wang DL. Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. European Journal of Heart Failure 2001;3:351-7.
29. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients, Lancet 2000;355:1575-81.
30. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
31. Suskin N, Sheth T, Negassa A, et al. Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. J Am Coll Cardiol 2001;37:1677-82.
32. Rees K, Taylor R, Singh S, et al. Exercise based rehabilitation for heart failure. Cochrane Library. Chichester: Wiley, 2004.
33. Hedman J, Kaprio J, Poussa T, et al. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study, Int J Epidemiol 1999;28:717-22.
34. Dudley NJ, Bowling A, Bond M, et al. Age- and sex-related bias in the management of heart disease in a district general hospital. Age Ageing 2002;31:37-42.
35. Brotons C, Permanyer G, Pacheco V, et al. Prophylactic treatment after myocardial infarction in primary care: how far can we go? Fam Pract 2003;20:32-5.
36. Brotons C, Calvo F, Cascant P, et al. Is prophylactic treatment after myocardial infarction evidence- based? Fam Pract 1999;16:94.
37. Sarasin FP, Maschiangelo ML, Schaller MD, et al. Successful implementation of guidelines for encouraging the use of beta blockers in patients after acute myocardial infarction. Am J Med 1999;106:499-505.
38. Newby LK, Bhapkar MV, White HD, et al. Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation. Journal of Thrombosis and Thrombolysis 2003;16:119-28.
39. Simpson E, Beck C, Richard H, et al. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Am Heart J 2003;145:438-44.
40. Cotter G, Shemesh E, Zehavi M, et al. Lack of aspirin effect: Aspirin resistance or resistance to taking aspirin? Am Heart J 2004;147:293-300.
41. Eagle KA, Kline-Rogers E, Goodman SG, et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med 2004;117:73-81.
42. Larosa JH, Larosa JC. Enhancing drug compliance in lipid-lowering treatment. Arc Fam Med 2000;9:1169-75.
43. Insull W. The problem of compliance to cholesterol altering therapy. J Intern Med 1997;241:317-25.
44. Ellis C, Shamini G, Majeed A. Prevalence and management of heart failure in general practice in England and Wales, 1994-1998. Health Statistics Quarterly 2001;11:17.
45. Cowie MR, McIntyre H, Panahloo Z. Delivering evidence-based care to patients with heart failure: results of a strucured programme. Cardiology in General Practice 2004;9:171-80.
46. Michalsen A, Konig G, Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart 1998;80:437-41.
47. Roe CM, Motheral BR, Teitelbaum F, et al. Angiotensin-converting enzyme inhibitor compliance and dosing among patients with heart failure. Am Heart J 1999;138:818-25.
48. Jolly K, Bradley F, Sharp S, et al. Randomised controlled trial of follow up care in general practice of patients with myocardial infarction and angina: final results of the Southampton heart integrated care project (SHIP). BMJ 1999;318:706-11.
49. Campbell NC, Thain J, Deans HG, et al. Secondary prevention in coronary heart disease: baseline survey of provision in general practice. BMJ 1998;316:1430-4.
50. Kotseva K, Wood D, De Backer G, et al. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries-principal results from EUROASPIRE II Euro heart survey programme. Eur Heart J 2001;22:554-72.
51. Flanagan DEH, Cox P, Paine D, et al. Secondary prevention of coronary heart disease in primary care: a healthy heart initiative. Monthly Journal of the Association of Physicians 1999;92:245-50.
52. Feder G, Griffiths C, Eldridge S, et al. Effect of postal prompts to patients and general practitioners on the quality of primary care after a coronary event (POST): randomised controlled trial. BMJ 1999;318:1522-6.
53. Fox KF, Wood DA, Wright M, et al. Evaluation of a cardiac prevention and rehabilitation programme for all patients at first presentation with coronary artery disease. J Cardiovasc Risk 2002;9:355-9.
54. Hippisley-Cox JJ, Pringle M, Crown N, et al. Sex inequalities in ischaemic heart disease in general practice: cross sectional survey. BMJ 2001;322:832-4A.
55. Carroll K, Majeed A, Firth C, et al. Prevalence and management of coronary heart disease in primary care: population-based cross-sectional study using a disease register. J Public Health Med 2003;25:29-35.
56. Corrigan M, Cupples ME, Stevenson M. Quitting and restarting smoking: cohort study of patients with angina in primary care. BMJ 2002;324:1016-17.
57. Harwich TB, Fonarow GC, Hamilton MA, et al. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol 2001;38:789-95.
58. Gustafsson F, Kragelund C, Torp-Pedersen C, et al. Effect of obesity and being overweight on long-term mortality in congestive heart failure: influence of left ventricular systolic function. Eur Heart J 2005;26:58-64.
59. Belardinelli R, Georgiou D, Cianci G, et al. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure-effects on functional capacity, quality of life, and clinical outcome. Circulation 1999;99:1173-82.
60. Unal B, Critchley JA, Capewell S. Missing, mediocre, or merely obsolete? An evaluation of UK data sources for coronary heart disease. J Epidemiol Community Health 2003;57:530-5.
61. Rutten FH, Grobbee DE, Hoes AW. Differences betweengeneral practitioners and cardiologists in diagnosis and management of heart failure: a survey in every-day practice. European Journal of Heart Failure 2003;5:337-44.